Clinical Trials Browser

Interventional × Recurrence × rovalpituzumab tesirine × Clear all

NCT02674568 2021-07-30

TRINITY

Phase 2 Completed

342 enrolled 18 charts

Recurrence, Small Cell Lung Carcinoma